Spectator by Seema Goswami: The data on kilo bites
But what if you are one of those old-fashioned people who wants to lose weight the natural way; ie without the benefit of weekly injections? Well, if you are one of those, then this column is for you. Here, based on my life-long experience of struggling with my weight, are just some tips for keeping the kilos off.
· I know that it is fashionable to sneer at portion control as a weight-loss method (though appetite suppressing drugs work on the same principle, more or less) but in my experience, it works a treat. So, if you are embarking on a diet journey, start by simply eating less of the bad stuff (fried food, white bread and rice, etc) and more of the good stuff (raw vegetables, leafy vegetables, beans and legumes, white meat, fish). Your transformation will be slow but it will also be steady and that's the kind of weight loss you want. The sensible thing is to leave the table when you are just 80%, as the Japanese do. (SHUTTERSTOCK)
· Learn to eat slowly, chewing each mouthful mindfully, instead of scoffing your meals down without a thought (and ideally, don't eat while in front of a screen, whether it is your TV, iPad or phone). This gives time for your satiety centres to get a message from your stomach that you are full.
· But don't keep eating until you are too full to manage even one more mouthful. The sensible thing is to leave the table when you are just 80% full – as the Japanese of Okinawa do; and who can deny that they are among the healthiest beings on the planet? – so that you retain just a smidgen of hunger rather than feeling overfull. Follow this 80% rule, known as Hara Hachi Bu, and see your health improve.
· Sometimes it is as important to fool your eyes as well as your mind. So, start using smaller plates and bowls to serve yourself. That way, your meals will look larger than they really are, and if you are eating mindfully and allowing those satiety signals to go through, then it is extremely unlikely that you will go back for seconds.
· Food pyramids make sense. So, do apportion the best part of your meal to good proteins and flavourful salads and vegetables (the base of your pyramid) and keep the unhealthy elements (the tip of the pyramid) to the minimum. But the order in which you eat what's on your plate is equally important. So, eat your salads and raw vegetables at the beginning of the meal. Not only will this make you feel full quicker, it will also regulate the release of sugar in your blood. And you know, when it comes to eating, it makes sense to save the best for the last!
From HT Brunch, June 28, 2025
Follow us on www.instagram.com/htbrunch
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Eli Lilly's daily GLP-1 pill shows strong weight loss results without food restrictions
In the first Phase 3 trial of its once-daily oral GLP-1 pill for obesity, drugmaker Eli Lilly reported that participants lost an average of 12% of their body weight after 72 weeks. The findings, announced Thursday in a company news release, come from a study of more than 3,127 adults who were overweight or obese with at least one weight-related health condition such as hypertension, but without diabetes. According to Lilly, participants taking the highest dose of the experimental pill, called orforglipron, lost an average of 27.3 pounds (12.4%). The results have not yet been peer-reviewed or published in a medical journal. Lilly already manufactures several injectable GLP-1 drugs, including Zepbound for obesity and Mounjaro and Trulicity for diabetes, but the company is now among several pharmaceutical firms racing to develop an effective pill form. Currently, the only GLP-1 pill on the market is approved for diabetes and comes with strict diet restrictions. Lilly says no food or water restrictions are needed with orforglipron, which can be taken at any time of day. Strong weight loss and heart health benefits The trial showed that 59.6% of people on the highest dose lost at least 10% of their body weight, while 39.6% lost at least 15%. Lilly also reported that the medication lowered markers of cardiovascular risk, including cholesterol and blood pressure. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 11 Foods That Help In Healing Knee Pain Naturally Undo Side effects were similar to injectable GLP-1 medications, with gastrointestinal issues being the most common. Nausea, constipation, and diarrhea were reported, with nausea affecting 29–34% of participants, slightly higher than the 25–29% seen in Zepbound trials. The company is also testing orforglipron in patients with type 2 diabetes and exploring whether the pill could help maintain weight loss after initial treatment with injectables. Potential role in long-term weight maintenance Some experts see potential for GLP-1 pills to serve as a follow-up treatment after injectable therapies. 'They may not be as effective for maximum weight loss as initial therapy but could be excellent for weight-loss maintenance, which is a different and arguably much more important destination for lasting health benefits,' Dr. Jody Dushay, assistant professor of medicine at Harvard Medical School and attending physician in endocrinology at Beth Israel Deaconess Medical Center, previously told CNN. Eli Lilly says it plans to submit orforglipron for regulatory review by the end of this year.
Time of India
4 hours ago
- Time of India
How Japanese walking can help with back pain and joint health
Many people suffer from chronic back and joint pain, which can make daily activities difficult. In fact , over a quarter of American adults report chronic lower-back or sciatic pain. Experts note that regular walking can reduce this pain, but a new variation called Japanese walking may provide extra benefits. Japanese walking is a structured interval-walking routine that alternates three minutes of brisk walking with three minutes of a slower pace, repeated for about 30 minutes. This low-impact exercise promotes an upright posture and core engagement, strengthening the muscles that support the spine and reducing strain on the back. What is Japanese Walking? Japanese walking (also called interval walking training) originated in Japan as a way to improve fitness without high stress on the body. In practice, you walk fast enough to raise your heart rate for three minutes, then slow down for three minutes to recover. Completing five of these six-minute cycles in a 30-minute session meets the standard guideline of 150 minutes of moderate activity per week. Importantly, this method emphasizes good posture: practitioners keep a tall spine, relaxed shoulders, and engage their abdominal muscles as they move. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Albu Sabah: Unsold Furniture Liquidation 2024 (Prices May Surprise You) Unsold Furniture | Search Ads Learn More Undo Spine and back benefits Japanese walking helps the spine by promoting alignment and core strength. Walking with an upright posture and a braced core keeps the back straight and reduces slouching. Dr. Arthur L. Jenkins III, board-certified neurosurgeon and founder of Jenkins NeuroSpine in New York City, confirmed in an interview with Fox News Digital, "I always encourage my patients to walk, and to engage their core (squeeze their abs and back) while walking to exercise more than just their legs, and straighten their backs.' By engaging abdominal and back muscles at each step, the exercise stabilizes the spine. This tall, aligned stance can help correct slouching and reduce back or neck strain. In other words, Japanese walking effectively turns a regular stroll into a gentle postural workout. Walking exercise in general has been linked to less back pain. A study published in JAMA Network found that people who walked over 100 minutes per day had about a 23% lower risk of chronic lower-back pain than those walking less. Japanese walking builds in this volume of walking in a safe way: doing a 30-minute session five times a week would meet that protective activity level. Because the pace alternates, participants get aerobic benefit and muscle engagement without overstraining the spine. Joint health benefits Unlike jogging or high-intensity training, Japanese walking is very gentle on the joints. Dr. Viola told Vogue that this style 'has the same benefits as more intense forms of exercise… just with less stress on your joints'. By spending most of the time at a moderate pace, it raises the heart rate without pounding the knees or hips. The slow recovery intervals give joints a chance to adjust before resuming the brisk pace. In fact, a study of people with knee osteoarthritis showed that walking in intervals did not increase knee pain, whereas a long continuous walk did. This suggests that interval walking like the Japanese method can improve fitness without aggravating joint pain. Japanese walking also strengthens the muscles around the joints, further protecting them. The alternating intensity works the thigh, hip, and core muscles more than a flat walk. Stronger muscles help stabilize joints during movement, easing the load on knees and hips. Because Japanese walking is low-impact but still effective, it is often recommended for middle-aged or older adults, or anyone wanting to protect their joints.
Scroll.in
10 hours ago
- Scroll.in
Heart and kidney diseases, cancer: What else can GLP-1 drugs treat in addition to obesity?
Research into the sugar-lowering powers of incretin hormones led to the discovery of GLP-1 drugs [like Ozempic and Mounjaro]. The added bonus of weight loss was serendipity. There seem to be many happy side effects of GLP-1 drugs. Of course, many of them are not because of the drugs themselves but because of weight loss. When you lose weight – whether through diet and exercise, bariatric surgery, or GLP-1 drugs – your knee pain and inflammation will reduce, heart health will improve, and so on. Yet it seems that GLP-1 drugs are directly improving health outcomes as well, apart from the benefits that accrue by reducing blood sugar and hunger. Dr Daniel Drucker, one of the scientists who discovered the GLP1 hormone, conducted an experiment on mice with systemic inflammation. When treated with GLP-1 drugs, the inflammation decreased. However, if the drug was blocked from reaching the brain, the inflammation did not reduce. This suggests that the brain plays a critical role in inflammation, and that reducing it may be directly mediated through the brain and not just indirectly due to weight loss. GLP-1 receptors – the switches activated by the drug – are found in the heart, liver, kidneys, pancreas, stomach, intestines and brain. As with many hormones, GLP-1's effects may not be limited to hunger and satiety alone but may also have multiple other functions. The full range of benefits these drugs can have in treating various diseases is still being discovered. In October 2018, Novo Nordisk, the company that holds the patent for semaglutide, began a trial to study the impact of the drug on the cardiovascular health of people who had heart disease and were overweight or obese but did not have diabetes. They enrolled over 17,000 people from diverse backgrounds. Their mean BMI was 33, and nobody was less than BMI 27. They were divided into two similar groups. One was given semaglutide (Wegovy) and the other was given a placebo. As the trial progressed, Covid-19 struck. Both groups saw similar rates of infection. Among the 184 who died of Covid-19, 78 had been taking semaglutide and 106 were on placebo. The difference is significant enough to suggest that the drug helped save some lives. In the trial, some died of reasons other than the pandemic. After accounting for all causes of death, those taking the drug saw 19 per cent fewer fatalities. No, this does not mean that GLP-1 drugs can be a treatment for Covid-19. What it does show is that the drug is improving overall health through weight loss and reduced inflammation. It confirms what we know about obesity: It's a disease. Did some of those patients survive the pandemic only because weight loss improved their overall health, or also because the drug reduced their inflammation levels, or were there more reasons? This is an open question because scientists are still discovering the full range of what GLP-1 drugs do inside the body. Their action on various diseases could help understand the disease better, perhaps aiding the discovery of new specific drugs and treatments for those diseases. GLP-1 drugs themselves could, some day, be prescribed for many of those conditions. It is important to note that research is ongoing and incomplete. Patients should not self-medicate. Even if GLP-1 drugs are approved by the US FDA or other regulators for some of these conditions, they must be used only under medical supervision. Here are some medical conditions in which GLP-1 drugs have been found to be helpful so far. Heart disease In March 2024, the US FDA approved Wegovy (semaglutide, same as Ozempic) for patients who had heart disease along with obesity or were overweight even if they did not have diabetes. This followed a large trial called SELECT (the same trial that showed the Covid-19 effect fortuitously), which had 17,600 patients enrolled in two groups. In the placebo group, 8 per cent of participants saw major adverse cardiovascular events (MACEs), such as heart attack, stroke or cardiovascular death. In the group taking semaglutide, the incidence was 6.5 per cent. That's a nearly 20 per cent reduction in risk. While this trial used weekly injectable semaglutide, the more recent SOUL trial, involving almost 10,000 participants, used oral semaglutide (Rybelsus) and showed a reduction in MACE of 14 per cent. Statins remain the main drug for people with heart disease, but these results demonstrate the role of semaglutide in the prevention of heart disease on top of statin therapy. Tirzepatide (GIP + GLP-1) has also been shown to reduce cardiovascular risk. In an international trial of 713 adults in nine countries, including the US, called the SUMMIT trial, participants with heart failure taking tirzepatide for two years had significantly improved cardiovascular health and reduced progression of heart failure. An analysis of 13 GLP-1 drug trials comprising more than 80,000 patients showed significant reductions in MACE, overall and cardiovascular mortality, stroke, and need for coronary procedures like angioplasty and surgery, regardless of the presence of diabetes. The benefits could not be explained by weight loss alone. These trials have led to guidelines that all people with diabetes and/or obesity who either suffer from or are at risk of heart disease should be treated with GLP-1 drugs. However, since people with diabetes and/or obesity are at higher risk of heart attack and stroke anyway, it is prudent to consider the prescription of these drugs in most people with diabetes even if they have no evidence of heart disease. Chronic kidney disease In January 2025, the US FDA approved the use of semaglutide in patients who have both diabetes and kidney disease. Our kidneys filter out toxins from the body and pass them through the urine. Their ability to do so starts declining in patients with diabetes. The FLOW trial showed that for patients with both type 2 diabetes and chronic kidney disease, taking semaglutide lowered the risk of complications (dialysis, need for transplant) by 24 per cent. It also slowed down the decline of their kidney function. Moreover, in a post hoc analysis of the SURPASS-4 randomised clinical trial, tirzepatide decreased protein excretion, slowed decline in kidney function and reduced death due to kidney causes in patients with type 2 diabetes. Cancer Since obesity raises the risk of some types of cancer, it is not surprising that studies have started finding a reduced incidence of cancer among those taking GLP-1 drugs. This is similar to the reduced risk of cancer seen among those who have undergone bariatric surgery. Obesity-related cancers are concentrated around the metabolic organs and, among women, around the reproductive organs as well. An observational study of 1.65 million patients in the US found a reduced risk of ten types of obesity-related cancers among diabetes patients taking GLP-1 drugs as compared to those on insulin. Another study found the risk of 13 types of cancer reduced by 22 per cent in those who underwent bariatric surgery and by 39 per cent among those who took GLP-1 drugs. Excerpted with permission from The Weight Loss Revolution, Ambrish Mithal and Shivam Vij, Juggernaut.
